Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.81 USD
Change Today -0.0189 / -2.28%
Volume 3.5K
CYCC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 9:36 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Snapshot

Open
$0.84
Previous Close
$0.80
Day High
$0.84
Day Low
$0.80
52 Week High
10/28/14 - $3.72
52 Week Low
02/3/15 - $0.51
Market Cap
27.9M
Average Volume 10 Days
220.6K
EPS TTM
$-0.84
Shares Outstanding
34.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (CYCC)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (CYCC) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (CYCC) Details

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue for the treatment of hematological cancers and solid tumors; and seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2, -7 and -9, which are central to the process of cell division and cell cycle control. Its oncology development programs also comprise CYC065, an orally-available 2nd generation CDK-2, -5, and -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer; and Aurora kinase inhibitors, a serine/threonine protein kinases that focuses on cell division, or mitosis for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/31/15
Founded in 1992

cyclacel pharmaceuticals inc (CYCC) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $530.6K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $324.4K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Pharmaceuticals, Inc. Declares Quarterly Cash Dividend on Convertible Exchangeable Preferred Stock, Payable on August 1, 2015

The board of Cyclacel Pharmaceuticals, Inc. declared a quarterly cash dividend in the amount of $0.15 per share on the company's 6% convertible exchangeable preferred stock. The cash dividend will be payable on August 1, 2015 to the holders of record of the preferred stock as of the close of business on July 17, 2015.

Cyclacel Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cyclacel Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $396,000 compared to $512,000 a year ago. Operating loss was $5,410,000 compared to $5,298,000 a year ago. Loss from continuing operations before taxes was $5,446,000 compared to $5,675,000 a year ago. Net loss from continuing operations was $4,877,000 or $0.25 per basic and diluted share compared to $4,912,000 or $0.19 per basic and diluted share a year ago. Net loss applicable to common shareholders was $4,919,000 or $0.25 per basic and diluted share compared to $4,962,000 or $0.25 per basic and diluted share a year ago. Research and development expenses were $4.3 million for each of the three months ended March 31, 2015 and March 31, 2014.

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 12, 2015

Cyclacel Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $0.81 USD -0.0189

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies
 

Industry Analysis

CYCC

Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.3x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.